Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 FAPI in Chemotherapy-Resistant Metastatic NSCLC
NCT07500285Phase 2Not yet recruiting
- Sponsor
- Prof. Dr. Cemil Taşcıoğlu Education and Research Hospital
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of Y-90 FAPI in non-small cell lung cancer (NSCLC), sponsored by Prof. Dr. Cemil Taşcıoğlu Education and Research Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Y-90 FAPI
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07500285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500285.